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Determinants of ligand binding 
and catalytic activity in the myelin 
enzyme 2′,3′-cyclic nucleotide 
3′-phosphodiesterase
Arne Raasakka1,2,3,4, Matti Myllykoski1,2, Saara Laulumaa1,2,4,5, Mari Lehtimäki1, 
Michael Härtlein6, Martine Moulin6, Inari Kursula1,3,4 & Petri Kursula1,2,3,4
2′,3′-cyclic nucleotide 3′-phosphodiesterase (CNPase) is an enzyme highly abundant in the central 
nervous system myelin of terrestrial vertebrates. The catalytic domain of CNPase belongs to the 2H 
phosphoesterase superfamily and catalyzes the hydrolysis of nucleoside 2′,3′-cyclic monophosphates 
to nucleoside 2′-monophosphates. The detailed reaction mechanism and the essential catalytic 
amino acids involved have been described earlier, but the roles of many amino acids in the vicinity 
of the active site have remained unknown. Here, several CNPase catalytic domain mutants were 
studied using enzyme kinetics assays, thermal stability experiments, and X-ray crystallography. 
Additionally, the crystal structure of a perdeuterated CNPase catalytic domain was refined at atomic 
resolution to obtain a detailed view of the active site and the catalytic mechanism. The results 
specify determinants of ligand binding and novel essential residues required for CNPase catalysis. 
For example, the aromatic side chains of Phe235 and Tyr168 are crucial for substrate binding, and 
Arg307 may affect active site electrostatics and regulate loop dynamics. The β5-α7 loop, unique for 
CNPase in the 2H phosphoesterase family, appears to have various functions in the CNPase reaction 
mechanism, from coordinating the nucleophilic water molecule to providing a binding pocket for the 
product and being involved in product release.
Myelin is a biologically unique cellular membrane structure, which envelops selected axonal segments in 
the nervous system and enables fast saltatory nerve impulse conduction and the correct functioning of 
the vertebrate nervous system1. A mature myelin sheath has two main morphological compartments. Its 
insulative nature is promoted by compact myelin, which is formed of tightly stacked lipid bilayers held 
together by a group of highly abundant myelin proteins2. Non-compact myelin has an important role in 
myelin maintenance, higher water content, and a different protein composition2,3.
2′ ,3′ -cyclic nucleotide 3′ -phosphodiesterase (CNPase) comprises 4% of total myelin protein in the 
central nervous system (CNS), being the most abundant CNS non-compact myelin protein4. CNPase 
is expressed as two isoforms through alternative splicing5,6. Both isoforms are abundantly expressed 
within the cytoplasmic compartment of non-compact myelin, while low levels of the isoform 2 mRNA 
are also detected in tissues outside the nervous system7,8. Isoform 2 is able to undergo mitochondrial 
import mediated by its N-terminal import sequence9. CNPase consists of an N-terminal polynucleotide 
kinase-like domain10, a catalytic phosphodiesterase domain11, and a membrane-anchored C-terminal tail, 
which contains a cysteine residue that undergoes isoprenylation12–14. CNPase is a potential autoantigen 
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in multiple sclerosis15, and variability in CNPase expression levels has been linked to neurological 
and psychiatric disorders, including Alzheimer’s disease, Down syndrome16, schizophrenia17–19 , and 
schizophrenia-related catatonic depression20. CNPase-deficient mice develop axonal swelling and degen-
eration, which further leads to progressive motor deficiencies and premature death21. In these mice, the 
inner tongue of myelin is most notably deformed, although myelin appears morphologically normal22.
The biological role of CNPase is unclear at the moment. CNPase might be involved in several cellular 
processes, since it interacts with RNA23,24, calmodulin24,25, and the cytoskeleton26,27. The significance of 
the latter in oligodendrocyte process outgrowth has been demonstrated in cell culture studies27. CNPase 
has also been shown to inhibit translation23, to modulate mitochondrial membrane permeability28, to 
inhibit the replication of several viruses29,30, and to have putative ATP/GTPase activity31. Additionally, 
CNPase can rescue yeast deficient in tRNA splicing in vivo, when the 2H domain of yeast tRNA ligase has 
been inactivated32. The structure, function, and significance of CNPase have recently been reviewed33.
The C-terminal phosphodiesterase domain is the best characterized domain of CNPase. This domain 
is highly conserved in mammalian CNPases34, and structurally and functionally, it belongs to the 2H 
phosphoesterase superfamily11,35,36, which includes several clades of enzymes involved in nucleotide or 
RNA metabolism37. The catalytic domain enables the rapid hydrolysis of nucleoside 2′ ,3′ -cyclic phos-
phates to nucleoside 2′ -phosphates34,38. The presence of endogenous adenosine 2′ ,3′ -cyclic monophos-
phate (2′ ,3′ -cAMP) was recently described in astrocytes, microglia39, and oligodendrocytes40. 2′ ,3′ -cAMP 
has putative biological functions in mitochondrial Ca2+ release28 and A2A adenosine receptor-mediated 
TNF-α inhibition41, and enzymatic 2′ ,3′ -cAMP depletion by CNPase upon traumatic brain injury has 
been suggested42,43.
We previously focused on the essential catalytic residues and the phosphodiesterase reaction mecha-
nism of CNPase34. Here, using a wide panel of mutations, not all directly affecting the catalytic residues, 
we investigated the active site of mouse CNPase catalytic domain (CNPcat) by biochemical and struc-
tural methods. Additionally, we characterized the perdeuterated CNPase catalytic domain (dCNPcat) and 
determined its crystal structure at 1.04-Å resolution, allowing the observation of active site protonation 
states and dynamics, as well as water networks. Altogether, our results provide a more detailed picture of 
the structure-function relationships in CNPase and shed light on the roles of several active-site residues 
involved in either direct or indirect ligand binding. The results allow to further understand substrate 
binding and specificity determinants in 2H phosphoesterases.
Results
The CNPase active site and its surroundings. To justify targets for mutagenesis, earlier knowledge 
on CNPase structure and activity was employed. The CNPase catalytic site, lying in a groove between 
two lobes, has pseudo two-fold symmetry and contains two apposing His-X-Thr-X (X denotes a hydro-
phobic residue) motifs, characteristic for 2H phosphoesterases (Fig.  1a)11,35,37. Four water molecules at 
the bottom of the active site also obey the two-fold symmetry36,38. Upon substrate binding, the His and 
Thr residues, together with the water molecules, coordinate the 2′ ,3′ -cyclic monophosphate group34. In 
mouse CNPase, this is done by His230, Thr232, His309, and Thr311, in a manner, where a nucleophilic 
water molecule activated by His309 can attack the cyclic phosphate and a pentavalent transition state 
is formed. His230 then donates a proton to the ribose 3′ -O atom, which acts as the leaving group, 
and a 2′ -phosphate product is formed34. In addition to hydrogen bonds to the His-X-Thr-X motifs and 
water molecules, the binding of ligands is mediated by two means (Fig. 1b,c): (1) the aromatic base of 
the nucleotide is sandwiched between the side chains of Phe235 and Val321, and (2) the ribose moiety 
forms C-H…π hydrogen bonds to the aromatic side chain of Tyr16838. The active-site cleft is also able 
to fit larger ligands, such as nicotinamide adenine dinucleotide phosphate (NADP+), and possibly even 
oligonucleotides34.
The cleft is flanked by two proline-containing loops (denoted α 3-β 2 and α 6-β 5, see Fig. 1a,d), and the 
β 5-α 7 loop in front of the active site core has a role during catalysis34. The β 5-α 7 loop leads into helix 
α 7, which is conserved in vertebrate CNPases, but absent in other 2H phosphoesterases36. This helix 
may be functionally important in determining CNPase stereospecificity44. In the vicinity of the bound 
nucleotide and the catalytic core, the side chain of Arg307 can swing towards and away from the active 
site and, therefore, could play a role in the catalytic cycle38.
The loops surrounding the active site could affect substrate binding and catalysis. Figure 1d presents 
a superposition of all CNPcat structures determined in this study (see below), showing flexibility that 
may be crucial to activity-related dynamics in CNPase.
Initial characterization of CNPase catalytic domain variants. In order to investigate the ligand 
binding properties of CNPcat, we expressed and purified CNPcat with the following mutations: H230Q, 
H309Q, H230S, H309S, T232A, T311A, F235A, F235L, V321A, R307Q, Y168A, Y168S, P225G, P296G, 
and H230Q/H309Q. In all cases, the proteins were straightforward to produce and behaved similarly 
to the wild-type protein during purification. The presence of the mutations was confirmed using DNA 
sequencing, mass spectrometry, and X-ray crystallography (Supplementary Table S1, Supplementary 
Table S2).
Mass spectrometry was used to examine hydrogen-deuterium exchange in CNPcat and dCNPcat 
(Supplementary Table S3). Comparing the measured mass of dCNPcat in D2O (25976.0 Da) with the 
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theoretical mass of 100% perdeuterated protein (26012.1 Da), the perdeuteration degree of dCNPcat was 
very high (97.9%). Additionally, the amount of exchanging protons and deuterons was in the same range 
for both samples (Supplementary Table S3), but not identical, indicating a small chemical difference 
between protons and deuterons.
Small-angle X-ray scattering (SAXS) and synchrotron radiation circular dichroism spectroscopy 
(SRCD) were used for quality control of CNPcat variant structure in solution (Supplementary Fig. S1, 
Supplementary Table S4). All mutants were folded, and in all cases, the radius of gyration, the maxi-
mum dimension, and the secondary structure content were similar to the wild-type protein. Hence, the 
point mutations did not significantly alter CNPcat folding. Additionally, thermal stability of dCNPcat 
(Tm = 57 °C, Supplementary Fig. S1) was similar to the hydrogenated protein34,45.
Essential catalytic residues. We next investigated the effect of mutations on catalysis (Table 1). In 
addition to activity assays, we crystallized all mutants and determined crystal structures with different 
active-site ligands (Supplementary Table S1).
Mutation of active-site histidine residues (H230Q, H230S, H309Q, H309S, and H230Q/H309Q double 
mutant) abolishes CNPase activity34. Overall, the structures of H230S, H309S34, H230Q, H309Q, and 
H230Q/H309Q are highly similar (Fig.  2a). However, only H230S and H309S could be used to trap 
nucleotide ligands within the active site, whereas H309Q and the H230Q/H309Q double mutant could 
not34. In H309S, an extra water molecule resides at the position of the missing imidazole ring, aiding in 
achieving correct binding coordination34.
In addition to the catalytic His mutants, near-complete catalytic inactivation is evident also in T232A, 
T311A, F235A, F235L, and Y168A (Table 1). The inactivation by the T232A and T311A mutations was 
expected35: threonine or serine is found in the catalytic motif in all 2H phosphoesterases, and in CNPcat, 
they are involved in all stages of catalysis, in achieving the correct substrate binding mode together with 
His230, His309, and the active-site water network. The catalytic activity in the case of T232A may not 
be completely lost, as T232A was crystallized in the presence of 2′ ,3′ -cAMP and excellent density for a 
reaction product is visible in the active site (Supplementary Fig. S2a). The time scale of crystallization 
and crystal storage far exceeds the slow enzymatic activity of the mutant.
Together with Val321, Phe235 has a direct role in substrate binding34,38,46. Both F235A and F235L 
mutations decrease kcat, although Phe235 is not directly involved in the enzymatic reaction. While 
Figure 1. The CNPase catalytic domain active site and essential ligand interactions. (a) Mouse CNPase 
catalytic domain with the active site 2H phosphoesterase family-signature His-x-Thr-x drawn as cylinders. 
Helix α 7 (light blue), unique to CNPase, as well as the dynamic α 3-β 2 (cyan), α 6-β 5 (dark green), and 
β 5-α 7 (orange) loops are highlighted. Additionally, the active-site water molecules are shown in red and the 
nucleophilic water in magenta. (b) A detailed view of the active site, with residues of interest to the current 
study indicated. Substrate (2′ ,3′ -cAMP, green) is in the active site, based on its coordinates in the H309S 
mutant complex structure. (c) Schematic illustration of the binding interactions of a substrate within the 
active site. (d) Stereo image of a superposition of all mutant structures obtained in this study, demonstrating 
loop flexibility in CNPcat.
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recognizing the caveat that the high KM for these mutants makes kcat rather inaccurate, this implies that 
the π -π stacking between Phe235 and the nucleotide base is not only required for substrate affinity, but 
it also may define correct substrate docking into a productive binding mode (Fig.  2b). Unproductive 
binding modes may lead to false interpretations of reaction kinetics47. In the F235L structure, the flexible 
active site β 5-α 7 loop (amino acids 319 – 321, see Fig.  1) is in the closed conformation. This loop is 
often found in a mixed conformation, and its conformation depends on the reaction step. The functional 
relevance of the β 5-α 7 loop will be discussed below.
Tyr168 is one of the aromatic residues on the CNPcat surface that we suggested to form a binding 
surface for RNA34. Tyr168 interacts with the substrate ribose moiety through C-H…π hydrogen bond-
ing38 (Fig. 1b,c). We carried out mutagenesis to study the role of the aromatic side chain of Tyr168. While 
the Y168A mutation decreases catalytic activity, Y168S retains it, albeit with an elevated KM compared 
to the wild-type enzyme. An increased KM, whilst retaining similar kcat, is an indication of decreased 
substrate binding affinity, with a minimal effect on actual catalysis. In the absence of the aromatic ring, 
the serine OH group appears to be enough to retain catalytic activity; this could be related to differences 
in water networks or overall dynamics in Y168A and Y168S. To further investigate the binding mode, 
we also attempted co-crystallization of CNPcat Y168S in the presence of 2′ ,3′ -cAMP, but even residual 
ligand density in the active site could not be observed. In the mutants, the missing ion-dipole interac-
tion between the Tyr168 hydroxyl group and the His230 imidazole ring apparently causes His230 and 
Ala/Ser168 to reposition in the active site by ~1 Å (Fig.  2c). Additionally, loop α 3-β 2 moves towards 
the active site by the same distance. These structural features suggest that Tyr168 also has a role in 
fine-tuning the active site conformation with its bulkiness.
Active-site dynamics. The complex with adenosine 2′ -monophosphate (2′ -AMP) reveals that 
the R307Q mutant binds the product in a mixed conformation, whereby only the phosphate position 
changes, and the β 5-α 7 loop also presents a linked double open/closed conformation (Supplementary 
Fig. S2b, Fig. 3a). Also, similarly to V321A34, R307Q presents an elevated KM, while kcat remains at the 
wild-type enzyme level. While Arg307 can be assumed to mainly affect ligand binding affinity, its mode 
of action is not entirely clear, as Arg307 makes no direct interactions with active site ligands in crystal 
variant
Phosphodiesterase activity (2ʹ,3ʹ-cNADP+ → 2ʹ-NADP+) Tm
kcat (s−1) KM (μM) kcat/KM (s−1 μM−1) °C
Wild type*,** 940 ± 38 553 ± 46 1.70 58.0
H230Q** 24 ± 15 1055 ± 1130 0.02 55.0
H309Q** – – – 52.7
H230S** 14 ± 14 1305 ± 2004 0.01 56.0
H309S** 21 ± 16 1192 ± 1468 0.02 57.3
H230Q & H309Q** – – – 49.7
F235A 183 ± 15 6253 ± 798 0.03 53.0
F235L 221 ± 15 3788 ± 434 0.06 55.3
T232A 231 ± 136 39648 ± 25605 < 0.01 57.7
T311A – – – 56.0
R307Q 1182 ± 205 2192 ± 548 0.54 59.0
V321A** 732 ± 33 1045 ± 77 0.70 59.5
Y168A 237 ± 7 1879 ± 122 0.13 53.7
Y168S 887 ± 98 1385 ± 235 0.64 53.7
P225G 1420 ± 60 483 ± 44 2.94 57.0
P296G 1332 ± 50 722 ± 51 1.73 60.0
Protein, solvent kcat (s−1) KM (μ M) kcat/KM (s−1 μ M−1) ° C
CNPcat, H2O* 807 ± 52 423 ± 76 1.91 60.0
CNPcat, D2O 273 ± 19 147 ± 38 1.85 61.0
dCNPcat, H2O 893 ± 57 382 ± 70 2.34 58.0
dCNPcat, D2O 326 ± 27 204 ± 57 1.59 59.0
Table 1.  Enzyme activity and thermal stability. All kcat and KM values are supplied with their respective 
standard errors. All Tm values were determined in the absence of ligands. *CNPcat and wild type here refer 
to the same protein, but the measured values have been determined at different times and therefore slightly 
vary from each other. The magnitude of variation is small. **The results have been discussed earlier (ref. 34) 
and are presented here for comparison.
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structures. Arg307 may be important for active-site electrostatics (Fig. 3b), likely playing a role in attract-
ing substrates to bind. Interestingly, Arg307 can have different conformations in crystal structures. In 
the substrate complex34, Arg307 is positioned towards the active site, like in the wild-type CNPcat apo 
structure38, whereas in R307Q, Gln307 is turned away – quite similarly to Arg307 in P296G complexed 
with 2′ -AMP (see next paragraph), and notably, in the sulphate complex determined earlier38, where 
wild-type CNPcat coordinates a sulphate ion at the nearby anion binding pocket (Fig. 3c). Gln307 sim-
ilarly coordinates a chloride ion in the anion binding pocket, together with Trp289 and the backbone 
amide of Gly305. In all structures, the 2.8-Å hydrogen bond between His230 Nδ 1 and the carbonyl O 
of residue 307 is retained, which results in a ~1 Å retraction of the main chain at position 307 in the 
sulphate complex38 and R307Q (Fig. 3c). In many structures, the side chain of Arg307 forms hydrogen 
bonds to a main-chain carbonyl group at the N-terminal end of helix α 7, suggesting its conformation 
may be linked to the opening and closing of the β 5-α 7 loop.
The structure of the CNPcat H230S mutant complexed with NADP+ 34 demonstrates that in addition 
to the reactive phosphate, the dinucleotide is predominantly bound via its adenine and nicotinamide 
bases and stabilized through the ribose moieties, whereas the pyrophosphate linker does not directly 
interact with the enzyme. We previously determined a V321A structure in complex with 2′ -AMP34, in 
which the β 5-α 7 loop was open. While we have also obtained structures with an open β 5-α 7 loop from 
other mutants and the wild-type protein in complex with products, this has been particularly easy with 
Figure 2. Inactivating mutations. (a) Superposition of all His230 and His309 mutant structures shows 
minimal molecular rearrangement within the active site. The additional water molecule that partially 
substitutes for the absent His309 imidazole in the H309S substrate complex structure is indicated (blue). 
(b) Superposition of Phe235 mutants with the H309S substrate complex demonstrates minimal molecular 
rearrangement in the active site, despite almost complete inactivation. (c) Mutations in Tyr168 result in 
minor molecular rearrangements in the active site, most notably at position 168, as well as at Pro225 and 
His230.
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V321A. This could relate to a higher binding affinity for the product, which would result in enzyme 
inhibition via hindered product release, and may explain the increased KM value34. To further investi-
gate the relevance of ligand size, we crystallized V321A in the presence of adenosine 2′ ,5′ -bisphosphate 
(2′ ,5′ -ADP), which, in addition to the 2′ -phosphate, also contains a 5′ -phosphate, thus mimicking the 
first 5′ -phosphate of an RNA molecule. We obtained structures in the space groups P21 and P212121, 
and both structures allowed us to analyze the ligand orientation in its entirety (Supplementary Fig. S2c). 
Figure 3. Several mutants highlight dynamics within the active site. (a) Superposition of R307Q with 
the H309S substrate complex and the V321A product complex demonstrate that in R307Q, the product 
2′ -phosphate can adopt different conformations, linked to the β 5-α 7 loop conformation. (b) Comparison of 
the surface electrostatics between wild-type CNPcat and R307Q reveals changes in the immediate proximity 
of the active site (arrow), caused by the absence of the positively charged Arg307. The catalytic site has 
been indicated with an orange dot. (c) The conformations of Arg307 in the sulphate complex and Gln307 
in R307Q suggest that Arg307 has a dynamic role, which is possibly related to the adjacent anion-binding 
pocket. In these two structures, this pocket is occupied by sulphate (cyan) and chloride (red), respectively. 
Conformational variability of Arg307 is evident also in the P296G structure. For clarity, only the substrate 
from the H309S structure is shown in the active site. (d) The presence of the 5′ -phosphate causes the ligand 
to retract slightly from the active site in V321A, but the β 5-α 7 loop remains open and the 2′ -phosphate 
is bound under it (arrow). (e) In P296G, the β 5-α 7 loop adopts the open conformation, similarly to the 
V321A structures, showing that loop opening is not caused by the absence of Val321. (f) Mutations from 
Pro to Gly at positions 225 and 296 affect loops α 3-β 2 and α 6-β 5, respectively. Loop α 6-β 5 is partially 
disordered in many structures.
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Similarly to V321A in complex with 2′ -AMP34, the 2′ ,5′ -ADP complexes show the β 5-α 7 loop the in 
the open conformation, with direct interactions between the 2´-phosphate and the N terminus of helix 
α 7 (Fig. 3d). The 5′ -phosphate is visible and extends out of the active site towards bulk solvent. In an 
RNA oligonucleotide, the 5′ -phosphate will be followed by another ribose and a base; several aromatic 
residues on the CNPase surface are in position to interact with these groups38.
Interestingly, the mutant P296G has a marginally higher kcat than the wild-type enzyme (Table 1). In 
the P296G structure, a 2′ -AMP product is present in the active site (Supplementary Fig. S2d). In contrast 
to the wild type enzyme, the adenine base is in a conformation similar to that seen in V321A before, and 
the β 5-α 7 loop has similarly adopted the open state (Fig. 3e). The latter, together with earlier liganded 
structures with an open β 5-α 7 loop34, suggests that loop opening is not an artifact caused by the V321A 
mutation, but rather a stabilized state so far not seen in crystal structures of the wild-type protein in 
complex with 2′ -AMP. Additionally, the activity is probably not hindered by the observed base-flipping 
phenomenon, as demonstrated by P296G. Furthermore, as mentioned above, Arg307 has moved slightly 
away from the active site to the general direction where Gln307 would reside in the R307Q structure 
and Arg307 in the sulphate complex38 (Fig. 3c). This, again, suggests that active site loop dynamics are 
linked to the conformation of Arg307.
Distal proline-containing loops. Pro225 and Pro296 reside in loops α 3-β 2 and α 6-β 5, respectively, 
flanking the edges of the active site – Pro296 near the adenine moiety and Pro225 on the 5′ -side of the 
ligand, next to Pro226 (Fig. 1b). The kcat values of P225G and P296G are slightly higher compared to the 
wild type enzyme (Table 1), most likely due to conformational flexibility offered by the glycine residues. 
P225G is the only mutant with an increased specificity constant (kcat/KM). We attempted to co-crystallize 
P225G in the presence of ligands. However, the reasonably low resolution (2.70 Å) crystal structure, 
which we obtained from crystals grown in the presence of reduced nicotinamide adenine dinucleotide 
2′ ,3′ -cyclic phosphate (2′ ,3′ -cNADP+), contains only poorly defined ligand density in the active site 
(Supplementary Fig. S2d). In P296G, which exhibits a higher kcat than wild-type CNPcat, while kcat/KM 
remains in similar range, the mutation-containing loop α 6-β 5 is disordered in the crystal structure, but 
adopts a different conformation compared to wild-type CNPcat (Fig. 3f).
Thermal stability and ligand binding. In order to investigate the ligand binding properties of 
CNPcat, we screened several ligands with differences in functional groups, measuring thermal stability 
midpoints (Tm), or “melting points”, of wild-type CNPcat and the mutants (Supplementary Fig. S3). The 
results indicate that all the variants were correctly folded and heat-stable, with the largest destabilization, 
8–9 °C, caused by the H230Q/H309Q double mutation. The catalytic motif, thus, is also important for 
CNPase stability. On the other hand, some mutant variants, such as P296G, even appeared slightly more 
stable than the wild-type protein.
Many of the ligands used in this study are known to bind CNPcat either from structures, enzyme 
activity assays34,48,49, or binding assays35. The CNPase mutants presented differences in Tm values with and 
without ligands, which included ones with variation in the monophosphate position (2′ -AMP, 3′ -AMP, 
5′ -AMP), ones with a hydrolysable cyclic phosphate (2′ ,3′ -cAMP, cytidine 2′ ,3′ -monophosphate 
(2′ ,3′ -CMP), 2′ ,3′ -cNADP+), the product from activity assays (NADP+), and adenosine 5′ -triphosphate 
(ATP) (Table  1, Fig.  4, Supplementary Fig. S3). The ligands mostly present the same trends in Tm 
for all protein variants (Fig.  4). Nearly all variants are slightly stabilized by all the acyclic adenosine 
monophosphates.
While for the substrates 2′ ,3′ -cAMP, 2′ ,3′ -cCMP, and 2′ ,3′ -cNADP+, the Tm values remain unchanged, 
differences are seen for reaction products. For NADP+, the Tm is generally much lower than for 2′ -AMP. 
NADP+ has a much larger interaction area with the enzyme between the two lobes34, and it destabilizes 
the fold to some extent. Additionally, ATP lowers the thermal stability of CNPcat. The binding mode of 
Figure 4. CNPcat thermal stability differences with ligand additives. The Tm values have been normalized 
to the Tm of each mutant in the absence of ligands.
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ATP is not known, but the data are indicative of an interaction. While thermal stability assays are a fast 
and easy way to assess qualitative differences in ligand binding, they should be interpreted with caution.
Deeper insights into catalysis from atomic-resolution crystallography. We prepared a perdeu-
terated variant of CNPcat and performed activity assays for perdeuterated and hydrogenated CNPcat 
with both H2O and D2O as reaction solvents. In H2O, dCNPcat exhibits similar kcat and KM to CNPcat. 
The kcat/KM is marginally higher, indicating that the enzyme is functioning slightly more specifically 
(Table  1). Changing the reaction solvent to D2O has a more profound effect. Here, kcat/KM remains 
similar, but both kcat and KM drop to approximately one third compared to the enzymes in H2O. Thus, 
dCNPcat remains chemically and functionally very similar to hydrogenated CNPcat, and the solvent 
effect has a much higher impact on catalysis than the isotope effect arising from perdeuteration. In D2O, 
the rapidly exchanging protons in the active site exchange to deuterons, and instead of regular hydro-
gen bonding, the ligands occupied in the active site experience stronger deuterium-mediated hydrogen 
bonds; in addition, reaction steps involving (de)protonation will surely be affected. KM indicates that the 
affinity towards substrate is higher, whereas kcat suggests that the rate-limiting step of catalysis is slower 
with deuterated reactive groups. To what extent each of these reflect the role of deuterated solvent, sub-
strate/product, and protein, remains to be studied.
As the thin crystals of dCNPcat could not be grown to dimensions suitable for neutron diffraction, 
the structure was solved using X-ray crystallography and refined to an atomic resolution of 1.04 Å. This 
is by far the highest resolution obtained for CNPase so far. Recently, a poorly characterized 2H family 
member, U6 snRNA biogenesis 1 protein, was refined at 1.1-Å resolution50.
The proposed catalytic mechanism for CNPase involves two histidine residues in the active site; 
His309 deprotonates and activates the nucleophilic water molecule, and His230 coordinates the leaving 
group and protonates it upon completion of the reaction34. Examination of the electron density maps for 
these residues confirms that in the apo state, His309 is deprotonated and His230 protonated (Fig.  5a). 
The result is well in line with the proposed mechanism, as well as the CNPase pH optimum value of 651.
The conserved water molecules at the bottom of the active site are well-defined in electron density. We 
observed difference electron density maps to detect locations of deuterium atoms, as at this resolution, 
for well-defined parts of the structure, they should be detectable for regions with low temperature factors. 
The water molecules in the active site are mobile enough to mask much of the difference density, but the 
surrounding chemical environment could be used in addition to define their orientations. The chain of 4 
water molecules at the bottom of the active site is coupled to another group of 4 water molecules above 
them – representing a true apo active site, without any bound buffer components (Fig. 5b). The outcome 
of a more detailed analysis is surprising; out of the 4 water molecules at the bottom, the central ones 
have 5 coordination contacts, while both of the distal ones only have 4, in a classical tetrahedral setting. 
This indicates that the two middle water molecules are possibly forming bifurcated, or three-centered, 
hydrogen bonds and/or may change their orientation upon ligand binding52. We expect both of them to 
be hydrogen bond donors when substrate binds.
As the active site of dCNPcat is empty in the crystal structure, we determined an additional structure 
of CNPcat with no ligand bound; this was successful when using the F235L mutant. All earlier structures 
have included either nucleotides or buffer components. The positions of the active-site water molecules, 
as well as side chain conformations of catalytic residues were nearly identical in dCNPcat and F235L, 
suggesting any changes in activity of dCNPcat are related to the replacement of H by D in the protein, 
solvent, and exchangeable sites of the substrate. Attempts to co-crystallize ligands within the active site 
of dCNPcat failed (unpublished data).
The highest resolutions obtained previously for CNPase were slightly better than 2.0 Å; hence, aniso-
tropic refinement has not been employed, and details of local disorder/flexibility have remained unre-
vealed. Anisotropic B factor refinement and alternative conformations reveal directional disorder in the 
vicinity of the catalytic cavity, for example concerning a number of aromatic residues (Fig. 5c). The dis-
order was partly built as alternative conformations, and partly dealt with by anisotropic refinement alone, 
depending on local electron density. The α 3-β 2 loop also exhibits a double conformation, showing it is 
flexible even in the crystal state. Residues with concerted disorder are likely to be involved, for example, 
in binding larger substrates, such as RNA.
At atomic resolution, it is not unusual to encounter side chain conformations violating geometric 
restraints. In the case of dCNPcat, the most drastic geometric outlier is Trp289, which is sandwiched 
through C-H…π interactions between Pro290 and Gly305. The side chain is bent, such that Cβ lies far 
from the plane of the aromatic ring. This feature is unambiguously defined in electron density. Such a 
conformation implies strain in the structure, and could be related to e.g. the anion binding pocket or the 
conformation of loop α 6-β 5 in the crystal structure. Overall, the atomic-resolution details on CNPase 
and its active site provide unprecedented detail on the structure-function relationships in 2H family 
enzymes.
Discussion
We characterized an array of CNPcat mutants using structural and biochemical approaches. Our results 
verify the roles of assisting amino acids in the phosphodiesterase active site and uncover crucial roles for 
Tyr168 and Phe235, which are required for correct substrate binding prior to catalysis.
www.nature.com/scientificreports/
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Active-site loops and Arg307 may function in regulating ligand binding through intramolecular 
dynamics. Taking our structural data together, we believe to have trapped distinct steps of the CNPase 
catalytic cycle (Fig.  6). Our observations allow us to speculate on active-site dynamics that take place 
during and after catalysis: The β 5-α 7 loop in both dCNPcat and F235L is closed, confirming the closed 
state of the active site in the apo form. In this state, Arg307 is situated close to the active site, and will 
remain so during the entry of a substrate. Initially, the substrate is locked in place through a hydrogen 
bonding network34, which allows the catalytic water molecule to be coordinated in a productive manner. 
During catalysis, the β 5-α 7 loop opens to expose the N terminus of helix α 7 and to provide space for the 
product, which still remains locked in a very similar orientation as the original substrate. This loop open-
ing might be modulated by the conformation of Arg307, since our R307Q structure demonstrates that 
in the absence of Arg307, the loop apparently has a much higher degree of freedom and adopts a mixed 
Figure 5. Atomic-resolution details of CNPcat. (a) 2Fo-Fc electron density for His230, His309, and the 
proximal water molecules is shown at 3σ . Density for an extra proton of His230 is visible in Fo-Fc maps 
contoured at 2.5 σ (purple). (b) Stereo image of the dCNPcat active site water network in the apo state. The 
hydrogen bonds are coloured as follows: backbone amide donating a hydrogen bond to water, blue; water 
donating a hydrogen bond to a backbone carbonyl, pink; hydrogen bonds that will bind the substrate cyclic 
phosphate, green; other hydrogen bonds between water molecules, yellow. (c) Anisotropic refinement reveals 
directional disorder of aromatic residues in the active site (at the right in this view) neighbourhood.
www.nature.com/scientificreports/
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open/closed conformation. Here, the product bound to the active site also adopts two conformations; 
when the loop is closed, the position is comparable to the pre-catalytic cyclic phosphate, and when open, 
the phosphate resides in the pocket under the β 5-α 7 loop (Fig. 3a). After catalysis, the loop remains in 
an open state until it collapses, possibly in an Arg307-regulated manner. This state with the closed loop 
and bound product we observed before with the wild-type protein38; the conformation is rather differ-
ent from the substrate and the product before loop collapse (Fig. 3e). The weakened hydrogen bonding 
between His230 and the ribose 3′ -OH in this state could contribute to product release. Details of the 
putative Arg307 conformational change remain unclear. Similarly, the free energy barriers and the micro-
scopic rate constants of each step, as well as the rate limiting step, remain undetermined at this time. 
Computational approaches are being planned to obtain more fine details on the CNPase catalytic cycle.
A conformational interplay between the β 5-α 7 loop and Arg307 is possible, and slight modulation 
of the active site coordination by conformational changes suggests that Arg307 could also otherwise be 
linked to active-site dynamics. For example, Arg307 could act as an affinity switch in substrate binding 
or product release through allosteric modulation by other factors, such as a ligand binding to the anion 
binding pocket. Our structural data indeed suggest a possibility to bind different anionic species to this 
pocket. Further characterization of the specificity of the anion binding pocket and its potential role in 
modulating the active site should also be undertaken.
The structural aspects discussed here provide new information about CNPase, which is a con-
served 2H phosphoesterase in its own clade and acts differently from several other members of the 2H 
superfamily. Yet, it is also important in the context of other 2H phosphoesterases to understand the 
CNPase catalytic cycle, not only in a mechanistic view, but in a more spatial-dynamic manner. CNPase 
is structurally unique with its helix α 7, which could be involved in stereospecificity and determination 
of substrate size and allows CNPases to function as 2′ ,3′ -cyclic phosphodiesterases, whereas other 2H 
phosphoesterases, like plant CPDases, can additionally hydrolyze 1″ ,2″ -cyclic ADP-riboses or are active 
on RNA substrates37. So far, we have only focused on adenine as a nucleotide base; for example, several 
modified bases that extend beyond the size of adenine have been described in tRNA molecules53. The 
destabilizing effect observed with ATP and NADP+ compared to 2′ -AMP is interesting, and incites to 
study even longer ligands, such as oligonucleotides with terminal 2′ ,3′ -cyclic or 2′ -phosphates, which are 
intermediate molecules in tRNA processing32,54,55 and can potentially function as endogenous RNA-like 
substrates for CNPase. To conclude, our results provide novel information about the ligand binding 
properties and dynamics of CNPase and evoke new future research directions for this peculiar enzyme 
and its homologues in the 2H family.
Methods
Cloning, mutagenesis, and protein production. Mutations were generated to CNPcat (amino 
acids 179 – 398) in the pTH27 expression vector45,56, using the QuikChange II site-directed mutagen-
esis kit (Agilent Technologies). The mutations were verified by DNA sequencing. The proteins were 
expressed using auto-induction and purified as described earlier45,57. Briefly, the proteins were expressed 
in Escherichia coli Rosetta(DE3) and purified using Ni-NTA affinity chromatography, followed by prote-
olytic His-tag cleavage58 and size-exclusion chromatography.
For producing dCNPcat, the CNPcat cDNA was subcloned into the pETNKI-his3C-LIC-Kan vector59. 
Protein production was carried out at the deuteration laboratory of the Partnership in Structural Biology 
in Grenoble (France), essentially as described60. dCNPcat was expressed in E. coli Rosetta (DE3) cells 
in minimal medium, with glycerol-d8 as the carbon source. Cells were adapted from fully hydrogenated 
to fully deuterated medium in six steps of 1:10 inoculation before cultivation and protein expression at 
+ 30 °C in a Labfors fermenter (Infors). The purification of dCNPcat was performed similarly to CNPcat. 
Figure 6. The CNPase reaction cycle. In the apo state, the β 5-α 7 loop is closed when a substrate enters. 
During catalysis, the product phosphate moiety flips into a cavity formed by the opening of the loop. The 
loop closes again, which results in product repositioning and release. The dashed lines represent the reaction 
step taking place in each state (from left to right: catalytic water activation by His309; nucleophilic attack to 
cyclic phosphate; protonation of ribose 3′ -O by His230). Note the subtle shift in Arg307 orientation during 
catalysis and loop movement (green asterisk).
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The protein purified in H2O buffers was exchanged back to deuterium oxide (D2O) by centrifugal ultrafil-
tration, whereby the protein was repeatedly concentrated and diluted back to a buffer containing 20 mM 
Bis-tris, 300 mM NaCl, 1% glycerol, 1 mM tris(2-carboxyethyl)phosphine hydrochloride (TCEP-HCl), 
pD 5.5, prepared in 99.90% D2O (EURISO-TOP).
Mass spectrometry. The mutations were verified using mass spectrometry. Accurate molecular 
masses were determined by liquid chromatography (LC)-coupled electrospray ionization time-of-flight 
mass spectrometry (ESI-TOF MS) in positive ion mode, using a Micromass Q-TOF 2 coupled with an 
ESI source. LC was performed using a Waters 2695 separation module with a Waters 2.1 mm × 10 mm 
reverse-phase MassPREP on-line desalting cartridge at + 20 °C. Protein sequences were verified using 
peptide fingerprinting by in-gel trypsin proteolysis and matrix-assisted laser desorption/ionization 
time-of-flight mass spectrometry (MALDI-TOF MS) with a Bruker Ultra fleXtreme mass analyzer. The 
matrix used was α -cyano-4-hydroxy cinnamic acid (Bruker).
The dCNPcat perdeuteration degree was determined using ESI-TOF MS. Separate samples of pure 
CNPcat and dCNPcat were mixed with an excess of either H2O or D2O, and their masses were deter-
mined using a Waters Acquity Synapt G2 mass analyzer with a Z-Spray ESI source and compared to 
theoretical values. To determine the amount of exchanging protons/deuterons, the exchange reaction 
mixtures were incubated at ambient temperature, the reactions were quenched by adding trifluoroacetic 
acid to 0.1% at different timepoints, and measurements were carried out immediately. The reactions were 
considered complete, when the measured masses seized to change. For rapid measurements, protein solu-
tions were directly injected into the ESI source and mass analyzer. The CNPcat total hydrogen amount 
was calculated using ProtParam61 and the amount of exchangeable protons using MS Tools62.
Small-angle X-ray scattering. SAXS data were collected from samples concentrated up to 7–9 mg/
ml in 20 mM Bis-tris, 300 mM NaCl, 10% glycerol, 1 mM TCEP-HCl, pH 5.5 on the ID14-3 BioSAXS 
beamline, European Synchrotron Radiation Facility (Grenoble, France) and the I911-4 Cassiopeia beam-
line, MAX-Lab (Lund, Sweden). Freshly prepared monomeric bovine serum albumin was used as a 
molecular weight standard. The data were processed and analyzed using BioXTAS RAW63 and ATSAS64. 
GNOM65 was used to calculate distance distribution functions.
Circular dichroism spectroscopy. To compare the secondary structure content of the CNPcat vari-
ants, SRCD data were collected from 1 mg/ml samples in 10 mM sodium phosphate, pH 7.0 on the CD1 
beamline at the ASTRID storage ring (ISA, Aarhus, Denmark) and on the UV-CD12 beamline at ANKA 
(KIT, Karlsruhe, Germany). The spectra were measured in 100-μ m quartz cuvettes at + 25 °C. Three 
scans of each sample from 280 to 170 nm were averaged, and the corresponding buffer spectrum was 
subtracted. The spectra were subjected to secondary structure deconvolution on DichroWeb66, using the 
CDSSTR algorithm and the SP175 reference database67,68.
Thermal stability of dCNPcat was analyzed using the Chirascan Plus spectropolarimeter (Applied 
Photophysics) as described69. The protein concentration was 0.25 mg/ml. The quartz cell had a pathlength 
of 0.5 mm, and the buffer consisted of 3 mM Bis-Tris (pH 5.5), 45 mM NaCl, 0.15% glycerol, and 0.15 mM 
TCEP-HCl. Spectra were measured continuously during heating from + 20 to + 90 °C, at a heating rate of 
1 °C/min. The data were analyzed using Global 3TM (Applied Photophysics).
Enzyme activity and thermal stability. Enzyme activity assays were carried out as described 
earlier using BIO-TEK Instruments Inc. PowerWave X, Tecan Infinite M200, and M1000Pro spectro-
photometers38,48. CNPcat catalyzes the conversion of 2′ ,3′ -cNADP+ to NADP+, which is further con-
verted to NAPDH by glucose-6-phosphate dehydrogenase in the presence of glucose-6-phosphate and 
MgCl2, and the absorbance at 340 nm is recorded as a function of time48. The substrate was 0.02 – 2 mM 
2′ ,3′ -cNADP+. The thermal stability of the mutants was assayed by exploiting the fluorescence intensity 
change of SYPRO Orange (Invitrogen) as described earlier34, including different ligands at 10 mM final 
concentration. The ligands included 2′ ,3′ -cAMP, 2′ -AMP, 3′ -AMP, 5′ -AMP, 2′ ,3′ -cCMP, NADP+, ATP, 
and 2′ ,3′ -cNADP+. Additionally, the enzyme activity and thermal stability of CNPcat and dCNPcat were 
assayed in both D2O and H2O. All activity and thermal shift assays were carried out in triplicate.
Protein crystallization, data collection, structure determination, and refinement. CNPcat 
mutants were crystallized using the setup described earlier34. Sitting-drop vapor diffusion was per-
formed against 85–100 μ l reservoir solution containing 20–35% (w/v) PEG3350, PEG4000, or PEG6000 
as precipitants and 50 mM Na acetate or 100 mM Na citrate, pH 3–5 as buffers at + 4 °C and + 20 °C. 
Protein solutions consisted of 250 μ M (6 mg/ml) protein in 20 mM Bis-tris, 300 mM NaCl, 10% glyc-
erol, 1 mM TCEP-HCl, pH 5.5. Co-crystallization experiments were used to incorporate ligands into 
the active site. Final concentrations of 5 or 10 mM ligand were added to the protein solutions. Ligands 
included 2′ ,3′ -cAMP, the Sp epimer of 2′ ,3′ -cyclic adenosine monophosphorothioate (2′ ,3′ -Sp-cAMPS), 
2′ ,3′ -cNADP+, and 2′ ,5′ -ADP. Each crystallization drop consisted of 0.5 μ l protein and 0.5 μ l reservoir 
solution. The crystallization conditions are shown in Supplementary Table S5. Both monoclinic and 
orthorhombic crystal plates grew even in the same drops. Before mounting, 1 μ l of a cryoprotectant 
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solution, consisting of reservoir solution supplemented with 23 – 25% PEG200 or PEG300, was added 
directly onto the drop.
Diffraction data were collected at 100 K on the synchrotron radiation beamlines X12, P13, and P14, 
EMBL/DESY (Hamburg, Germany) and I911-2, MAX-Lab (Lund, Sweden). Data were processed using 
XDS70. Phasing was done with molecular replacement using the mouse CNPcat (PDB ID 2xmi38) as 
the search model in Phaser71. Structure refinement was performed in phenix.refine72 and model build-
ing in Coot73. Apart from the highest-resolution structures, automatic optimization of the refinement 
weighting scheme was applied. The structures were validated and analyzed using DSSP74, MolProbity75, 
PyMOL, UCSF Chimera76, APBS77,78, and CCP4mg79. Data collection and refinement statistics are listed 
in Supplementary Table S1. Since all individual structure refinement procedures included both molecular 
replacement, building of solvent regions and ligands, addition of hydrogen atoms to riding positions, a 
number of cycles of manual rebuilding, and refinement until convergence, the test set of reflections was 
individually selected for each dataset. All discussed features were clearly visible in electron density maps, 
and model bias is not a concern. Recently, it was shown that refinement to convergence alone is enough 
to remove model bias80.
Crystallization of dCNPcat was based on conditions optimized for CNPcat38. The crystal used for data 
collection was grown using hanging-drop vapor diffusion on Nextal X plates at + 8 °C. The well solution 
consisted of 50 mM acetate, 25% PEG3350, pD 3.5. Cryoprotection was done by adding 20% PEG200. 
The crystal was cryo-cooled in liquid nitrogen prior to data collection on beamline I911-3 (MAX-Lab). 
Processing, structure solution, and refinement were performed as above. Anisotropic B factors were 
refined, and deuterium atoms were added to their riding positions.
PDB references. Catalytic domain of mouse 2′ ,3′ -cyclic nucleotide 3′ -phosphodiesterase, with muta-
tions H230Q and H309Q, 4wbi
Catalytic domain of mouse 2′ ,3′ -cyclic nucleotide 3′ -phosphodiesterase, with mutation F235A, 4wbl
Catalytic domain of mouse 2′ ,3′ -cyclic nucleotide 3′ -phosphodiesterase, with mutation F235L, 4wc9
 Catalytic domain of mouse 2′ ,3′ -cyclic nucleotide 3′ -phosphodiesterase, with mutation H230Q, com-
plexed with citrate, 4wca
Catalytic domain of mouse 2′ ,3′ -cyclic nucleotide 3′ -phosphodiesterase, with mutation H309Q, 4wcb
Catalytic domain of mouse 2′ ,3′ -cyclic nucleotide 3′ -phosphodiesterase, with mutation P225G, 4wcc
 Catalytic domain of mouse 2′ ,3′ -cyclic nucleotide 3′ -phosphodiesterase, with mutation P296G, com-
plexed with 2′ -AMP, 4wda
 Catalytic domain of mouse 2′ ,3′ -cyclic nucleotide 3′ -phosphodiesterase, with mutation R307Q, com-
plexed with 2′ -AMP, 4wdb
 Catalytic domain of mouse 2′ ,3′ -cyclic nucleotide 3′ -phosphodiesterase, with mutation T232A, com-
plexed with citrate, 4wdd
 Catalytic domain of mouse 2′ ,3′ -cyclic nucleotide 3′ -phosphodiesterase, with mutation T232A, com-
plexed with 2′ -AMP, 4wfr
Catalytic domain of mouse 2′ ,3′ -cyclic nucleotide 3′ -phosphodiesterase, with mutation T311A, 4wde
 Catalytic domain of mouse 2′ ,3′ -cyclic nucleotide 3′ -phosphodiesterase, with mutation V321A, com-
plexed with 2′ ,5′ -ADP, 4wdf
 Catalytic domain of mouse 2′ ,3′ -cyclic nucleotide 3′ -phosphodiesterase, with mutation V321A, com-
plexed with 2′ ,5′ -ADP, 4wdg
Catalytic domain of mouse 2′ ,3′ -cyclic nucleotide 3′ -phosphodiesterase, with mutation Y168A, 4wdh
Catalytic domain of mouse 2′ ,3′ -cyclic nucleotide 3′ -phosphodiesterase, with mutation Y168S, 4wex
Perdeuterated catalytic domain of mouse 2′ ,3′ -cyclic nucleotide 3′ -phosphodiesterase, 5ae0
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